A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers

c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. While responses to c-Met inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or mutations. We developed a c-Met targeted antibod...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Biol Ther
Egile Nagusiak: Fujita, Ryo, Blot, Vincent, Wong, Eley, Stewart, Christine, Lieuw, Vincent, Richardson, Robyn, Banah, Ammar, Villicana, Jose, Timmer, Anjuli, Coronella, Julia, Newman, Roland, Gymnopoulos, Marco
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2020
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515515/
https://ncbi.nlm.nih.gov/pubmed/32192391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1737490
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak